Diacomit Alternatives Compared
| Diacomit (stiripentol) | Epidiolex (cannabidiol) | Fintepla (fenfluramine) |
|
|---|
| Diacomit (stiripentol) | Epidiolex (cannabidiol) | Fintepla (fenfluramine) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Dravet Syndrome. Diacomit may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Dravet Syndrome, Lennox-Gastaut Syndrome, Tuberous Sclerosis Complex. Epidiolex may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Dravet Syndrome, Lennox-Gastaut Syndrome. Fintepla may also be used for purposes not listed in this medication guide. |
Related suggestions Dravet Syndrome
|
|||||||||||||||||||||||
| More about Diacomit (stiripentol) | More about Epidiolex (cannabidiol) | More about Fintepla (fenfluramine) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Epidiolex has an average rating of 5.3 out of 10 from a total of 4 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 50% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Diacomit side effects |
View all Epidiolex side effects |
View all Fintepla side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Diacomit prices |
View all Epidiolex prices |
View all Fintepla prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
13 hours |
61 hours |
20 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 615 drugs are known to interact with Diacomit:
|
A total of 617 drugs are known to interact with Epidiolex:
|
A total of 832 drugs are known to interact with Fintepla:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
August 20, 2018 |
June 25, 2018 |
June 25, 2020 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.